Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.
Osteoarthritis (OA), the most common of all arthritic conditions, is a social and financial burden to all nations. The most recent research has significantly advanced our understanding of the cause of OA and risk factors associated with it. These findings have provided useful information that has helped in the daily management of patients with OA. Some preventative measures and a number of therapeutic agents and drugs are available, which may help to reduce the progression of OA in certain patients. Moreover, the most recent progress in research has significantly enhanced our knowledge of the factors involved in the development of the disease and of the mechanisms responsible for its progression. This has allowed identification of several new therapeutic targets in a number of pathophysiological pathways. Consequently, the field is opening up to a new era in which drugs and agents that can specifically block important mechanisms responsible for the structural changes that occur in OA can be brought into development and eventually into clinical trials.
Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre-Dame Hospital, Montreal, Quebec, Canada. dr@jppelletier.ca
Jean-Pierre
JP
Pelletier
Johanne
J
Martel-Pelletier
Jean-Pierre
JP
Raynauld
D018501:Antirheumatic Agents / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D010003:Osteoarthritis / Q000628:therapy*; D010597:Pharmacogenetics; D012219:Rheumatology / Q000639:trends*
D018501:Antirheumatic Agents